[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341103-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341103-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","single-cell-lineage-tracing-reveals-clonal-dynamics-of-anti-egfr-therapy-resistance-in-triple-negative-breast-cancer","Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer","","Triple-negative breast cancer (TNBC) shows frequent EGFR gene amplification, yet anti-EGFR treatment produces inconsistent responses. To explain this variability, the study uses cellular barcoding and single-cell transcriptomics to reconstruct subclonal dynamics of EGFR-amplified TNBC under afatinib, an irreversible EGFR tyrosine kinase inhibitor. Integrated lineage tracing identifies a rare pre-existing subpopulation with elevated IGFBP2, which makes TNBC cells tolerant by activating IGF1-R compensatory signaling. Mechanism-informed deep learning then predicts afatinib sensitivity and supports individualized treatment strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/single-cell-lineage-tracing-reveals-clonal-dynamics-of-anti-egfr-therapy-resistance-in-triple-negative-breast-cancer/341103/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/single-cell-lineage-tracing-reveals-clonal-dynamics-of-anti-egfr-therapy-resistance-in-triple-negative-breast-cancer/341103.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do anti-EGFR therapies show inconsistent outcomes in triple-negative breast cancer?","Question",{"text":63,"@type":64},"Although many primary TNBCs amplify EGFR and increase EGFR expression, clinical responses to anti-EGFR therapies vary widely, and EGFR status does not significantly correlate with response. The study attributes inconsistency to non-genomic resistance mechanisms revealed at the subclonal level.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the study reconstruct resistance dynamics after afatinib treatment?",{"text":68,"@type":64},"It uses cellular barcoding and single-cell transcriptomics to rebuild the subclonal dynamics of EGFR-amplified TNBC cells exposed to afatinib, then integrates lineage tracing to identify surviving lineages and their biological signatures.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does IGFBP2 play in afatinib resistance?",{"text":72,"@type":64},"A rare pre-existing subpopulation with elevated IGFBP2 is identified. IGFBP2 overexpression is sufficient to render TNBC cells tolerant to afatinib by activating compensatory IGF1-R signaling.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341103,1790862798,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Pellecchia etal. Genome Medicine (2024) 16:55 [https://doi.org/10.1186/s13073-024-01327-2](https://doi.org/10.1186/s13073-024-01327-2)  \nGenome Medicine  \n RESEARCH Open Access  \nSingle cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer  \nSimona Pellecchia 1,4†, Melania Franchini 1,3†, Gaetano Viscido1,2, Riccardo Arnese1,3 and Gennaro Gambardella1*  \nAbstract  \nBackground Most primary Triple Negative Breast Cancers (TNBCs) show amplification of the Epidermal Growth Factor Receptor (EGFR) gene, leading to increased protein expression. However, unlike other EGFR-driven cancers, targeting this receptor inTNBC yields inconsistent therapeutic responses.  \nMethods To elucidate the underlying mechanisms ofthis variability, we employ cellular barcoding and single-cell transcriptomics to reconstruct the subclonal dynamics of EGFR-amplified TNBC cells in response to afatinib, a tyrosine kinase inhibitor (TKI) that irreversibly inhibits EGFR.  \nResults Integrated lineage tracing analysis revealed a rare pre-existing subpopulation of cells with distinct biological signature, including elevated expression levels of Insulin-Like Growth Factor Binding Protein 2 (IGFBP2) . We show that IGFBP2 overexpression is sufficient to renderTNBC cells tolerant to afatinib treatment by activating the compensatory insulin-like growth factor I receptor (IGF1-R) signalling pathway. Finally, based on reconstructed mechanisms of resistance, we employ deep learning techniques to predict the afatinib sensitivity ofTNBC cells.  \nConclusions Our strategy proved effective in reconstructing the complex signalling network driving EGFR-targeted therapy resistance, offering new insights for the development of individualized treatment strategies inTNBC.  \n†Simona Pellecchia and Melania Franchini contributed equally to the work.  \n*Correspondence: Gennaro Gambardella [gambardella@tigem.it](gambardella@tigem.it)  \n1 Telethon Institute of Genetics and Medicine, Naples, Italy  \n2 Department of Chemical, Materials and Industrial Engineering , University of Naples Federico II, Naples, Italy  \n3 Department of Electrical Engineering and Information Technology, University of Naples Federico II, Naples, Italy  \n4 Scuola Superiore Meridionale, Genomics and Experimental Medicine Program, Naples, Italy  \nBackground  \nTriple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive breast cancer subtype characterized by metastatic progression, poor prognosis, and the absence of targetable biomarkers [1–3]. Neoadjuvant chemotherapy is initially highly effective on TNBCs but about 30%–50% of the patients rapidly develop resistance associated with higher mortality [1, 2, 4]. Despite Epidermal Growth Factor Receptor (EGFR)-activating mutations and amplifications (≥5 copies) are uncommon in TNBC [3, 5–7], the majority of primary TNBCs exhibit enhanced expression of EGFR because of an increase in gene copy number (three to four copies) [7–12](Additional File 1: Fig. S1A-F), thus representing a valuable vulnerability for TNBC patients [13]. However, unlike other tumour types where inhibition of wild-type EGFR  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, ","cbCaiozfTP0cpjJN","https://ap.wps.com/l/cbCaiozfTP0cpjJN","pdf",3684879,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## TNBC heterogeneity and clinical resistance\n## Limits of EGFR biomarkers\n# Single-cell approaches","[{\"question\":\"Why do anti-EGFR therapies show inconsistent outcomes in triple-negative breast cancer?\",\"answer\":\"Although many primary TNBCs amplify EGFR and increase EGFR expression, clinical responses to anti-EGFR therapies vary widely, and EGFR status does not significantly correlate with response. The study attributes inconsistency to non-genomic resistance mechanisms revealed at the subclonal level.\"},{\"question\":\"How does the study reconstruct resistance dynamics after afatinib treatment?\",\"answer\":\"It uses cellular barcoding and single-cell transcriptomics to rebuild the subclonal dynamics of EGFR-amplified TNBC cells exposed to afatinib, then integrates lineage tracing to identify surviving lineages and their biological signatures.\"},{\"question\":\"What role does IGFBP2 play in afatinib resistance?\",\"answer\":\"A rare pre-existing subpopulation with elevated IGFBP2 is identified. IGFBP2 overexpression is sufficient to render TNBC cells tolerant to afatinib by activating compensatory IGF1-R signaling.\"}]","Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer | PDF",1790040334,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80d58eec0f20fc158199a761c0d6e965.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/406924c0d9a595c25666d4998337c796.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c5f4d2ea54e18e434896be2f901605d.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13584b16e31fe71ad37488c3891f3bc3.webp",980,1301]